SG11201400567QA - Cd40l-specific tn3-derived scaffolds and methods of use thereof - Google Patents

Cd40l-specific tn3-derived scaffolds and methods of use thereof

Info

Publication number: SG11201400567QA
Authority: SG; Singapore
Prior art keywords: cd40l; methods; specific; derived scaffolds; scaffolds
Prior art date: 2011-10-11

Application number

SG11201400567QA

Inventor

Anthony Coyle

Manuel Baca

Thomas Thisted

Stacey Drabic

Luba Grinberg

Shabazz Novarra

Vaheh Oganesyan

Ronald Herbst

David Kenneth Spencer

Original Assignee

Medimmune Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-11

Filing date

2012-10-10

Publication date

2014-05-29

2012-10-10 Application filed by Medimmune Llc filed Critical Medimmune Llc

2014-05-29 Publication of SG11201400567QA publication Critical patent/SG11201400567QA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

SG11201400567QA 2011-10-11 2012-10-10 Cd40l-specific tn3-derived scaffolds and methods of use thereof SG11201400567QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161546028P	2011-10-11	2011-10-11
PCT/US2012/059477 WO2013055745A2 (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof

Publications (1)

Publication Number	Publication Date
SG11201400567QA true SG11201400567QA (en)	2014-05-29

Family

ID=48082729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201707813YA SG10201707813YA (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof
SG11201400567QA SG11201400567QA (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201707813YA SG10201707813YA (en)	2011-10-11	2012-10-10	Cd40l-specific tn3-derived scaffolds and methods of use thereof

Country Status (22)

Country	Link
US (4)	US10000553B2 (en)
EP (2)	EP2771022B1 (en)
JP (4)	JP6140712B2 (en)
KR (3)	KR20220116585A (en)
CN (3)	CN108948196B (en)
AU (1)	AU2012323316B2 (en)
BR (1)	BR112014008804A2 (en)
CA (1)	CA2851667A1 (en)
CY (1)	CY1123690T1 (en)
DK (1)	DK2771022T3 (en)
ES (1)	ES2819075T3 (en)
HK (1)	HK1201463A1 (en)
HR (1)	HRP20201513T1 (en)
HU (1)	HUE051439T2 (en)
LT (1)	LT2771022T (en)
MX (2)	MX367013B (en)
PT (1)	PT2771022T (en)
RS (1)	RS60828B1 (en)
RU (2)	RU2019133467A (en)
SG (2)	SG10201707813YA (en)
SI (1)	SI2771022T1 (en)
WO (1)	WO2013055745A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE047164T2 (en) *	2007-11-01	2020-04-28	Univ Arkansas	Compositions and methods of enhancing immune responses to eimeria
HUE051439T2 (en) *	2011-10-11	2021-03-01	Viela Bio Inc	Cd40l-specific tn3-derived scaffolds and methods of use thereof
MA41044A (en)	2014-10-08	2017-08-15	Novartis Ag	COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
US9938356B2 (en)	2014-11-10	2018-04-10	Medimmune Limited	Binding molecules specific for CD73 and uses thereof
BR112017019401A2 (en)	2015-03-12	2018-05-02	Medimmune, Llc	albumin fusion protein purification method
KR101810778B1 (en) *	2015-06-23	2017-12-20	서울대학교산학협력단	CD154 binding polypeptide and its use
MY188405A (en)	2015-08-05	2021-12-08	Janssen Biotech Inc	Anti-cd154 antibodies and methods of using them
US11958913B2 (en) *	2017-01-09	2024-04-16	Biomunex Pharmaceuticals	Polypeptide linker for preparing multispecific antibodies
US11905313B2 (en) *	2017-11-28	2024-02-20	The United States of America, as represented by the Secretary, Department of Health and Human Services.	Recombinant RSV G proteins and their use
AU2019347730A1 (en) *	2018-09-24	2021-03-25	Janssen Biotech, Inc.	Method of providing safe administration of an anti-CD154 antibody
CA3114394A1 (en) *	2018-09-26	2020-04-02	Viela Bio, Inc.	Cd40l antagonist and uses thereof
US20220090055A1 (en) *	2018-10-24	2022-03-24	Brandeis University	Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128
EP3902824A4 (en)	2018-12-28	2023-01-04	Sparx Therapeutics Inc.	Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases
CN111440253B (en) *	2019-01-17	2021-08-27	中国科学院上海药物研究所	Cubic cyclodextrin framework-RGD composition and preparation method thereof
IL308488A (en) *	2021-05-21	2024-01-01	Viela Bio Inc	Cd40l antagonist and uses thereof in the treatment of lupus nephritis

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en)	1990-03-20	1994-11-24	Trustees Of Columbia University In The City Of New York, The	Chimeric antibodies with receptor binding ligands in place of their constant region
DE69112207T2 (en)	1990-04-05	1996-03-28	Roberto Crea	"WALK-THROUGH" MUTAGENESIS.
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
US5843701A (en)	1990-08-02	1998-12-01	Nexstar Pharmaceticals, Inc.	Systematic polypeptide evolution by reverse translation
US5866344A (en)	1991-11-15	1999-02-02	Board Of Regents, The University Of Texas System	Antibody selection methods using cell surface expressed libraries
FR2686899B1 (en)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5440018A (en)	1992-05-20	1995-08-08	The Green Cross Corporation	Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH08501085A (en)	1992-08-26	1996-02-06	プレジデントアンドフェローズオブハーバードカレッジ	Use of cytokine IP-10 as an antitumor agent
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
WO1996008513A1 (en)	1994-09-16	1996-03-21	The Scripps Research Institute	Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
EP0985039B1 (en)	1997-06-12	2008-02-20	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
BR9908226A (en)	1998-02-25	2000-10-24	Lexigen Pharm Corp	Improvement of the circulating half-life of fusion proteins based on antibody
AU731758B2 (en)	1998-07-08	2001-04-05	Mitsui Chemicals, Inc.	Method for secretory production of human growth hormone
CA2341029A1 (en)	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
AU775997B2 (en)	1998-12-02	2004-08-19	Bristol-Myers Squibb Company	DNA-protein fusions and uses thereof
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
EP2154535A1 (en)	1998-12-10	2010-02-17	Bristol-Myers Squibb Company	Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
DK1196637T3 (en)	1999-07-27	2007-07-30	Adnexus Therapeutics Inc	Peptide ligation methods
US7022479B2 (en)	2000-01-24	2006-04-04	Compound Therapeutics, Inc.	Sensitive, multiplexed diagnostic assays for protein analysis
ES2564161T3 (en)	2000-07-11	2016-03-18	Research Corporation Technologies, Inc	Artificial antibody polypeptides
JP2004526419A (en)	2000-10-16	2004-09-02	フィロスインク．	Protein scaffolds for antibody mimics and other binding proteins
ES2649037T3 (en)	2000-12-12	2018-01-09	Medimmune, Llc	Molecules with prolonged half-lives, compositions and uses thereof
US6951725B2 (en)	2001-06-21	2005-10-04	Compound Therapeutics, Inc.	In vitro protein interaction detection systems
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
EP2339017A3 (en)	2002-03-29	2011-10-12	Genencor International, Inc.	Enhanced protein expression in bacillus
WO2003104418A2 (en)	2002-06-06	2003-12-18	Research Corporation Technologies, Inc.	Reconstituted polypeptides
CA2489348A1 (en)	2002-06-24	2003-12-31	Genentech, Inc.	Apo-2 ligand/trail variants and uses thereof
KR100524872B1 (en)	2003-12-04	2005-11-01	씨제이 주식회사	Processes for the purification of interferon beta
AU2004296376B2 (en)	2003-12-05	2010-03-04	Bristol-Myers Squibb Company	Inhibitors of type 2 vascular endothelial growth factor receptors
US9012369B2 (en)	2004-07-06	2015-04-21	Pfizer Inc.	Look-through mutagenesis for developing altered polypeptides with enhanced properties
KR100852415B1 (en)	2004-07-13	2008-08-18	재단법인서울대학교산학협력재단	- Polypeptide and derivatives thereof containing novel heparin-binding site derived from human tenacin C
GB0416651D0 (en)	2004-07-26	2004-08-25	Proteo Target Aps	Polypeptide
BRPI0610470A2 (en) *	2005-05-26	2010-06-22	Seattle Genetics Inc	isolated antibody or antigen-binding fragment that specifically binds human cd40, kit, pharmaceutical composition, and isolated polynucleotide
JP4959226B2 (en)	2006-05-19	2012-06-20	独立行政法人産業技術総合研究所	Three finger-like protein library
WO2008031098A1 (en)	2006-09-09	2008-03-13	The University Of Chicago	Binary amino acid libraries for fibronectin type iii polypeptide monobodies
BRPI0719597A2 (en)	2006-11-22	2013-12-17	Adnexus A Bristol Myers Squibb R & D Company	OBJECTIVE THERAPEUTIC PRODUCTS BASED ON HANDLED PROTEINS FOR TYROSINE KINASE RECEPTORS, INCLUDING IGF-IR
CN104825433A (en)	2007-07-03	2015-08-12	达努塔·克鲁谢夫斯卡	New medical use of alfa-ketoglutarate
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en)	2007-08-10	2014-06-26	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
CA2704229C (en)	2007-10-31	2019-05-07	Medimmune, Llc	Protein scaffolds comprising seven beta strand domains and six loop regions
US20100322930A1 (en)	2007-12-27	2010-12-23	Frank Kolbinger	Fibronectin-based binding molecules and their use
WO2009133208A1 (en)	2008-05-02	2009-11-05	Novartis Ag	Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (en)	2008-05-22	2011-07-21	ブリストル−マイヤーズスクイブカンパニー	Scaffold domain protein based on multivalent fibronectin
EP2352521B1 (en) *	2008-10-14	2020-09-16	Genentech, Inc.	Immunoglobulin variants and uses thereof
PL2356269T3 (en)	2008-10-31	2016-12-30		Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (en)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	Bispecific egfr/igfir binding molecules
CN102596992B (en)	2009-02-12	2015-09-09	詹森生物科技公司	Based on the holder combination thing of III type fibronectin domain, method and purposes
WO2010128142A1 (en)	2009-05-07	2010-11-11	Novozymes Biopharma Dk A/S	Method for purifying albumin
EP2464663A4 (en)	2009-08-13	2013-05-29	Massachusetts Inst Technology	Engineered proteins including mutant fibronectin domains
CN102741280B (en)	2009-10-30	2015-12-02	诺维信生物制药丹麦公司	Albumin variants
WO2011051466A1 (en) *	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
ES2678144T3 (en)	2010-02-16	2018-08-09	Medimmune, Llc	Compositions related to SAH and methods of use
WO2011130324A1 (en) *	2010-04-13	2011-10-20	Medimmune, Llc	Fibronectin type iii domain-based multimeric scaffolds
KR20180129991A (en)	2010-11-05	2018-12-05	노파르티스 아게	Methods of treating rheumatoid arthritis using il-17 antagonists
JP2014177354A (en)	2011-07-05	2014-09-25	Asahi Glass Co Ltd	Window glass
HUE051439T2 (en) *	2011-10-11	2021-03-01	Viela Bio Inc	Cd40l-specific tn3-derived scaffolds and methods of use thereof
GB2512156A (en)	2012-11-08	2014-09-24	Novozymes Biopharma Dk As	Albumin variants
JP2017515828A (en)	2014-05-19	2017-06-15	メディミューンリミテッド	Treatment for rheumatoid arthritis
BR112017019401A2 (en)	2015-03-12	2018-05-02	Medimmune, Llc	albumin fusion protein purification method
CA3114394A1 (en)	2018-09-26	2020-04-02	Viela Bio, Inc.	Cd40l antagonist and uses thereof

2012
- 2012-10-10 HU HUE12840074A patent/HUE051439T2/en unknown
- 2012-10-10 MX MX2014004065A patent/MX367013B/en active IP Right Grant
- 2012-10-10 KR KR1020227028109A patent/KR20220116585A/en not_active IP Right Cessation
- 2012-10-10 EP EP12840074.4A patent/EP2771022B1/en active Active
- 2012-10-10 CN CN201810653215.1A patent/CN108948196B/en active Active
- 2012-10-10 DK DK12840074.4T patent/DK2771022T3/en active
- 2012-10-10 SG SG10201707813YA patent/SG10201707813YA/en unknown
- 2012-10-10 JP JP2014535807A patent/JP6140712B2/en active Active
- 2012-10-10 RS RS20201146A patent/RS60828B1/en unknown
- 2012-10-10 RU RU2019133467A patent/RU2019133467A/en unknown
- 2012-10-10 CA CA2851667A patent/CA2851667A1/en active Pending
- 2012-10-10 AU AU2012323316A patent/AU2012323316B2/en active Active
- 2012-10-10 LT LTEP12840074.4T patent/LT2771022T/en unknown
- 2012-10-10 PT PT128400744T patent/PT2771022T/en unknown
- 2012-10-10 KR KR1020147012468A patent/KR102132997B1/en active IP Right Grant
- 2012-10-10 WO PCT/US2012/059477 patent/WO2013055745A2/en active Application Filing
- 2012-10-10 EP EP20177799.2A patent/EP3753567A1/en active Pending
- 2012-10-10 BR BR112014008804A patent/BR112014008804A2/en not_active Application Discontinuation
- 2012-10-10 RU RU2014117511A patent/RU2704992C2/en active
- 2012-10-10 CN CN201280049742.2A patent/CN103874501B/en active Active
- 2012-10-10 SG SG11201400567QA patent/SG11201400567QA/en unknown
- 2012-10-10 ES ES12840074T patent/ES2819075T3/en active Active
- 2012-10-10 KR KR1020207019515A patent/KR102434073B1/en active IP Right Grant
- 2012-10-10 CN CN202211152182.5A patent/CN116063509A/en active Pending
- 2012-10-10 SI SI201231843T patent/SI2771022T1/en unknown
- 2012-10-10 US US14/347,016 patent/US10000553B2/en active Active
2014
- 2014-04-03 MX MX2019009104A patent/MX2019009104A/en unknown
2015
- 2015-03-02 HK HK15102049.0A patent/HK1201463A1/en unknown
2017
- 2017-05-01 JP JP2017090963A patent/JP6539300B2/en active Active
2018
- 2018-05-31 US US15/993,964 patent/US11104720B2/en active Active
2019
- 2019-06-07 JP JP2019106642A patent/JP7068231B2/en active Active
2020
- 2020-09-22 HR HRP20201513TT patent/HRP20201513T1/en unknown
- 2020-10-02 CY CY20201100927T patent/CY1123690T1/en unknown
2021
- 2021-07-28 US US17/387,269 patent/US11555062B2/en active Active
2022
- 2022-04-28 JP JP2022073975A patent/JP2022115916A/en active Pending
- 2022-11-01 US US18/051,704 patent/US20230242619A1/en active Pending

Also Published As

Publication number	Publication date
KR20220116585A (en)	2022-08-23
US20180312572A1 (en)	2018-11-01
PT2771022T (en)	2020-09-14
HK1201463A1 (en)	2015-09-04
US11555062B2 (en)	2023-01-17
AU2012323316A1 (en)	2014-03-20
MX2014004065A (en)	2014-08-22
LT2771022T (en)	2020-12-10
MX2019009104A (en)	2019-09-10
US20220089688A1 (en)	2022-03-24
SG10201707813YA (en)	2017-11-29
ES2819075T3 (en)	2021-04-14
CN103874501B (en)	2018-07-20
SI2771022T1 (en)	2020-12-31
EP2771022A4 (en)	2015-08-05
JP6140712B2 (en)	2017-05-31
DK2771022T3 (en)	2020-09-28
US20230242619A1 (en)	2023-08-03
HRP20201513T1 (en)	2020-12-11
WO2013055745A2 (en)	2013-04-18
EP2771022B1 (en)	2020-07-01
RU2704992C2 (en)	2019-11-01
JP2019205433A (en)	2019-12-05
JP2015501147A (en)	2015-01-15
JP6539300B2 (en)	2019-07-03
KR20200085376A (en)	2020-07-14
JP2022115916A (en)	2022-08-09
US11104720B2 (en)	2021-08-31
EP2771022A2 (en)	2014-09-03
RU2014117511A (en)	2015-11-20
US10000553B2 (en)	2018-06-19
RS60828B1 (en)	2020-10-30
JP2017195884A (en)	2017-11-02
CN108948196A (en)	2018-12-07
US20150098955A1 (en)	2015-04-09
AU2012323316B2 (en)	2017-08-10
KR102434073B1 (en)	2022-08-18
HUE051439T2 (en)	2021-03-01
CY1123690T1 (en)	2022-03-24
JP7068231B2 (en)	2022-05-16
RU2019133467A (en)	2020-07-06
CN116063509A (en)	2023-05-05
KR20140077199A (en)	2014-06-23
CN103874501A (en)	2014-06-18
MX367013B (en)	2019-08-02
BR112014008804A2 (en)	2017-06-13
EP3753567A1 (en)	2020-12-23
CN108948196B (en)	2022-09-23
WO2013055745A3 (en)	2013-08-01
CA2851667A1 (en)	2013-04-18
KR102132997B1 (en)	2020-07-14

Publication	Publication Date	Title
HRP20181628T1 (en)	2018-12-14	Compounds and their methods of use
HK1201463A1 (en)	2015-09-04	Cd40l-specific tn3-derived scaffolds and methods of use thereof cd40l- tn3-
HK1208439A1 (en)	2016-03-04	5-azaindazole compounds and methods of use 5-
EP2912178A4 (en)	2016-05-25	Super-enhancers and methods of use thereof
IL227440B (en)	2019-01-31	Ballstent device and methods of use
EP2672820A4 (en)	2014-09-03	Mannoside compounds and methods of use thereof
EP2675471A4 (en)	2015-01-28	Hsa-related compositions and methods of use
ZA201401653B (en)	2019-09-25	Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201303793B (en)	2014-07-30	Substituted quinoline compounds and methods of use
EP2721063A4 (en)	2015-01-14	Pcsk9-binding polypeptides and methods of use
EP2670866A4 (en)	2015-09-02	Biomarkers and methods of use thereof
HK1254533A1 (en)	2019-07-19	Bioprobes and methods of use thereof
EP2766078A4 (en)	2015-03-25	Ventilation devices and methods of use
EP2852397A4 (en)	2016-03-23	Huwentoxin-iv variants and methods of use
EP2709999A4 (en)	2014-11-19	Quinazoline-7-ether compounds and methods of use
EP2670245A4 (en)	2014-07-02	Alpha-ketoheterocycles and methods of making and using
IL215720A0 (en)	2011-12-29	Dehumidifier and method of use thereof
ZA201405829B (en)	2015-10-28	Cleaning arrangement and method of use
GB2493595B (en)	2014-09-10	Wheelchair and method of construction
GB201102364D0 (en)	2011-03-30	Lock means and method of use thereof
GB201122402D0 (en)	2012-02-08	Lock means and method of use thereof
GB201101586D0 (en)	2011-03-16	Lock means and method of use thereof
GB201014490D0 (en)	2010-10-13	Cleaning means and method of use thereof